Warren Lammert is the Founder and CIO Granite Point Capital, a public/private investment firm started in 2004 and located in Boston. Warren began his career in finance as a research associate with Fred Alger Management in New York City in 1984 and has over 35 years of investment experience as an analyst and portfolio manager. He is a graduate of Yale University and the London School of Economics where he completed an MSc in Economic History with Distinction. He is a CFA® charter holder.
Warren has worked to support new therapies in epilepsy over the last twenty five years. He is the co-founder of Epilepsy.com and the Epilepsy Therapy Project and is a past chairman of the Epilepsy Foundation. In recent years, Warren has served in board roles with companies developing new therapies for epilepsy including Biscayne Neurotherapeutics (acquired by Supernus Pharma in 2018), Engage Therapeutics (acquired by UCB in 2020), and Cerebral Therapeutics where he served as board chair. He is also on the board of Receptor Therapeutics which is advancing new therapies to treat anxiety. He is also a co-founder and the chairman of Tevard Biosciences, a company developing gene therapies for Dravet syndrome and other rare disorders.
Warren’s interests include Chinese language, European and Chinese economic history, ice-hockey, squash and running.
